Cancer Translational Medicine

Original Research | Open Access

Vol.8 (2022) | Issue-2 | Page No: 63-75


Differential Expression of T-box Transcription Factor TBX19 Regulates the Progression of Hepatocellular Carcinoma

Guifang He1, Yanjiao Hu2, Fuguo Dong3, Changchang Liu1, Duo Cai1, Shihai Liu1*


1. Medical Animal Laboratory, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China

2. Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China

3. Medical Record Management Center, the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China

Corresponding Author

Address for correspondence: Dr. Shihai Liu, Medical Animal Laboratory, the Affiliated Hospital of Qingdao University, No.1677 Wutaishan Road, Changjiang Road District, Qingdao 266400, Shandong, China. E-mail: 

Important Dates  

Date of Submission:   24-Jan-2022

Date of Acceptance:   30-May-2022

Date of Publication:   28-Jun-2022


Aim: Hepatocellular carcinoma (HCC) is a leading cause of global cancer-related mortality, the prevalence of which is rising annually. HCC patients exhibit poor prognosis due to a lack of predictive biomarkers associated with the early stages of the disease, underlining the need for more research into the molecular drivers of this malignancy in order to better guide its diagnosis and treatment. The T-box (TBX) transcription factor family encodes a series of regulators of tumor cell development. In light of this, we aim to study the impact of TBX19 on the growth of HCC cells.

Methods: Using the UALCAN database, we conducted a series of bioinformatics analyses assessing the prognostic relevance of TBX19 in HCC and the association between the expression of this gene and patients’ clinicopathological findings. In addition, a series of proliferation, and migration assays were performed to assess the relationship between TBX19 and HCC cell malignancy. Furthermore, the effects of TBX19 overexpression on deoxythymidylate kinase (DTYMK) were evaluated through Western blotting and measurements of deoxyribonucleoside triphosphate (dTTP) levels.

Results: Bioinformatics analysis revealed that the TBX19 overexpression was associated with a poor prognosis in HCC patients. Further, a strong correlation between TBX19 overexpression and the overall survival of patients was observed. Functional assays indicated that TBX19 was able to promote HCC cell proliferation and migration while also regulating DTYMK and DTYMK-related dTTP levels.

Conclusions: Overexpression of TBX19 is associated with poor prognosis in HCC patients. Further, exogenous TBX19 expression could promote the in vitro growth of HCC cells, underscoring the promise of TBX19 as a target for future efforts aimed at diagnosing and treating this cancer type.

Keywords: T-box 19, hepatocellular carcinoma, proliferation, migration, deoxyribonucleoside triphosphate


Primary liver cancers are the sixth and third most common causes of cancer and cancer-related mortality in the world, respectively, with only lung cancer and colorectal cancer being responsible for higher rates of patient death.[1] Hepatocellular carcinoma (HCC) accounts for 75%-85% of all liver cancer cases, and an estimated 900,000 cases of primary liver cancer were diagnosed in 2020 with 800,000 corresponding deaths according to the GLOBOCAN 2020 database.[1] Liver cancer cases in China account for approximately 55% of the total global caseload, underscoring the major threat to public health that this tumor type represents.[2] While there have been major breakthroughs in diagnosing and treating HCC, many patients nonetheless exhibit a poor prognosis attributable to the high rates of recurrence and metastasis associated with this cancer.[3] There is thus an urgent need to further explore the molecular mechanisms governing HCC malignancy and progression in an effort to define more reliable diagnostic tests and therapeutic interventions for affected patients.[4],[5],[6],[7]

The T-box (TBX) transcription factor family consists of a range of regulatory proteins that play essential roles in governing early embryogenesis and other stages of development.[8] TBX abnormalities are commonly observed in a range of heritable human diseases, including TBX1, TBX3, TBX5, and TBX22 mutations in patients with DiGeorge syndrome, Ulnar-Mammary syndrome, Holt-Oram syndrome, and cleft palate with ankyloglossia, respectively.[LinkRef 9-900] Several recent studies have additionally highlighted a potential link between specific TBX genes and certain malignancies.[10] For example, the downstream Wnt/β-catenin signaling targets, TBX2 and TBX3, are commonly overexpressed and mutated in breast and ovarian cancer, respectively, in addition to being associated with malignant melanoma, pancreatic cancer and HCC.[11],[12],[13],[14],[15],[16],[17],[18],[19] The TBX19 transcription factor, which harbors a conserved T-box DNA binding motif, is reportedly expressed at elevated levels in colorectal cancer, pituitary corticotroph tumors, and cells bearing KRAS mutations.[20],[21]

Deoxythymidylate kinase (DTYMK), a nuclear deoxythymidylate kinase, catalyzes the process of deoxy-TMP phosphorylation.[22] This enzyme plays a vital role in DNA synthesis in vivo and is a key intermediate enzyme in many pyrimidine analog drug-related pathways.[23] Previous studies have shown that DTYMK is a probable predictive factor of poor prognosis in non-small cell lung cancer (NSCLC) and may be a potential therapeutic target for the disease. Yeh et. al., mentioned that DTYMK might have relevance to the poor prognosis of HCC patients, but its importance has not yet been evaluated.[24]

The specific clinical relevance and functional importance of TBX19 in individual cancers, however, remain to be fully clarified. In this analysis, we found TBX19 to be overexpressed in HCC patient clinical samples, with the knockdown of this gene being sufficient to suppress the proliferative and migratory activity of HCC cells. Moreover, we found TBX19 to regulate DTYMK, which catalyzes the penultimate step in deoxyribonucleoside triphosphate (dTTP) biosynthesis. Together, the results of this study indicate that TBX19 expression can promote the in vitro growth of HCC cells, underscoring the promise of TBX19 as a target for future efforts aimed at diagnosing and treating liver cancer.


UALCAN database analyses

The Cancer Genome Atlas (TCGA)-based UALCAN ( database,[25] constructed using PERL-CGI, javascript, and CSS, enables online mining analyses. Using this database, we were able to assess the expression of TBX19 in both HCC tumors and control tissues, in addition to examining relative expression levels in different stages of HCC. This database was additionally used to examine the relationship between gene expression and patient prognosis.

Cell culture and reagents

The Huh7, HepG2, and SNU387 liver cancer cell lines and the control LX-2 cell line were obtained from Procell (Wuhan, China) and cultured in DMEM (Gibco, USA) supplemented with 10% fetal bovine serum (FBS) in a 5% CO2 incubator. STR identification was used to validate all cell lines.

Western blotting

RIPA buffer (Beyotime Institute of Biotechnology, China) containing PMSF (1 nM; Invitrogen) was used to lyse cells, after which the levels of protein in the collected extracts were measured via BCA assay (Thermo Fisher Scientific Inc., Waltham, MA). Proteins were then separated via 10% SDS-PAGE and transferred to PVDF membranes (Millipore), which were subsequently probed overnight with anti-TBX19 (1:1500, Abcam, MA, USA), anti-DTYMK (1:1000, Abcam), or anti-GAPDH (1:3000, Abcam). Secondary HRP-conjugated anti-rabbit (1:5000) or anti-mouse (1:5000) IgG (Abcam) were then used to detect protein bands, which were imaged with a Bio-Rad ChemiDoc XRS+ system (Hercules, CA, USA).

Real-time quantitative polymerase chain reaction (qPCR)

An RNeasy Mini Kit (Qiagen, Hilden, Germany) was used to isolate total RNA from cells, after which an iScript cDNA synthesis kit (Bio-Rad Laboratories, CA, USA) was used to prepare cDNA. For qPCR analyses, samples were analyzed using Takara SYBR Premix Ex Taq (Tli RNaseH Plus, Japan) and a real-time qPCR instrument (Mode: FTC-3000P, Funglyn Biotech, Toronto, Canada) with the following thermocycler settings: 94°C for 4 min; 40 cycles of 94°C for 20 s, 60°C for 10 s, and 72°C for 20 s. All primers used in this study are compiled in Table 1, with GAPDH serving as a normalization control. Relative gene expression was measured via the 2-ΔΔCt approach.[26]

Cellular transfection

For overexpression studies, full-length TBX19 cDNA was amplified and cloned into the GV141 vector (Genechem, China). TBX19-specific siRNA constructs (siR1, siR2, and siR3) and a negative control construct (siNC) were obtained from GenePharma Co. (Shanghai, China). Cells were plated into 6-well plates and transfected with appropriate constructs using Lipofectamine 3000 (Invitrogen, USA) based on provided directions, as in prior report.[27] All siRNA sequences are compiled in Table 1.


Table 1.
Table 1. Sequences of primers for qPCR and siRNA sequence


CCK-8 assay

A Cell Counting Kit-8 (CCK-8, Dojindo, MD, USA) was used based on provided directions to monitor cellular proliferation. Briefly, Huh7 or SNU387 cells (2 × 103 cells/well) were added to 96-well plates and cultured for appropriate periods of time, with absorbance at 450 nm (OD450) recorded every 24 h over a 4-day period.

5-Ethynyl-2'-Deoxyuridine (EdU) uptake assay

A BeyoClick EdU Cell Proliferation Kit with Alexa Fluor 555 (Beyotime, China) was utilized based on provided directions to monitor cell proliferation, as in previous reports.[28] Briefly, cells were rinsed two times using phosphate buffered saline (PBS) prior to incubation for 4 h in an EdU working solution (10 μM) at 37°C while protected from light. Cells were then rinsed two additional times with PBS, fixed for 15 min with 4% paraformaldehyde (PFA), permeabilized for 15 min using 0.1% Triton-X100, and rinsed thrice using PBS. DAPI (4',6-diamidino-2-phenylindole, Boster, China) was then employed to counterstain cells for 5 min, after which they were imaged using a fluorescence microscope (Celenas, Nikon, Tokyo, Japan) at 100× magnification. DAPI (blue) and EdU (red) fluorescence respectively corresponded to DNA replication and nuclei.

Colony formation assay

Cells transfected with appropriate siRNAs or overexpression vectors were plated and incubated at 37°C for 6-9 days, after which media was discarded, cells were washed with PBS, and methanol was used to fix colonies for 30 min followed by crystal violet staining and imaging with a Nikon camera.

Transwell assays

Transwell assays were used to assess cellular migration, as in prior reports.[28] Media supplemented with 20% FBS was added to the lower chamber of each well as a chemoattractant. After a 24 h incubation, non-migratory cells were removed with a cotton swab, while the remaining cells were stained with crystal violet prior to imaging. The mean number of cells in 10 (100×) fields of view were counted to quantify migration. All analyses were performed in duplicate for a minimum of three times.

LinkedOmics analysis

The publicly available LinkedOmics platform ( enables analyses of multiomics datasets from 32 tumor types included in the TCGA database.[29] The LinkedOmics LinkFinder module enables users to search for attributes related to a particular attribute of interest, and was used in this report to identify genes that were differentially expressed in a manner correlated with TBX19 expression in the TCGA liver cancer cohort. Spearman’s correlation coefficients and heat maps, scatter plots, or volcano plots were used to analyze the resultant data. Data were additionally ranked, and transcription factor target enrichment analyses were conducted using GSEA. Rank criteria were as follows: false discovery rate (FDR) < 0.05, with 1,000 replicate simulations performed.

Deoxyribonucleoside triphosphate (dTTP) extraction and quantification

In total, 106 cells were treated with 60% chilled methanol to prepare extracts, which were then immersed in a 100°C dry bath for 3 minutes. Samples were then dried under vacuum, as in prior reports,[28] the remaining residues were then suspended in 80 µl of nuclease-free dH2O. The dTTP levels in these samples were then measured as reported previously.[28]

Statistical analysis

Statistical analysis was performed using SPSS 22.0 (SPSS Inc, NY, USA) and GraphPad Prism 5.0.1 (GraphPad Software, NY, USA). Data are means ± SEM from three or more replicate experiments. Data were compared via two-tailed Student’s t-tests, while survival analyses were conducted using the log-rank test. Correlations between TBX19 and DTYMK were analyzed via Spearman’s test. P < 0.05 was the threshold of significance for this study.


Analysis of TBX19 expression in the UALCAN database

We began by using the UALCAN database to assess TBX19 expression in a range of tumor types, revealing differences between tumors and normal tissues. In 24 tumor samples studied, TBX19 was found upregulated in 15 samples and downregulated in 9 samples. TBX19 expression was found to be elevated in BLCA, CHOL, COAD, ESCA, GBM, HNSC, KIRC, KIRP, LIHC, LUAD, LUSC, PCPG, READ, SARC, and STAD relative to normal tissues, with similar upregulation in other tumors [Supplementary Figure 1].

We further used this database to perform subgroup analyses of LIHC cases, including 371 primary tumors and 50 normal tissues, and found that TBX19 mRNA levels were significantly elevated in primary tumors (P < 1×10-12) [Figure 1A]. In addition, TBX19 levels were significantly increased in stage 3 liver cancer as compared to normal tissue or stage 1/2 liver cancer (normal vs. stage 1, P = 5.83×10-12; normal vs. stage 2, P = 3.94×10-14; normal vs. stage 3, P = 2.33×10-15; normal vs. stage 4, P = 4.58 ×10-2) [Figure 1B]. The Kaplan-Meier plotter tool additionally indicated that the overall survival of HCC patients exhibiting high TBX19 expression was significantly lower than that of patients expressing lower levels of this gene (log-rank P <  0.0001) [Figure 1C]. As such, lower levels of TBX19 expression are associated with a better HCC patient prognosis.


Figure 1
Figure 1. Association between the expression of TBX19, clinicopathological parameters, and prognostic outcomes in patients with HCC. (A) TBX19 expression in HCC samples from the UALCAN database. (B) TBX19 expression levels in different HCC stages in the UALCAN database. (C) The relationship between TBX19 expression and prognostic outcomes in the KM plotter online database.


TBX19 controls HCC cellular migratory and proliferative activity

To determine how TBX19 affects HCC cell malignancy, we examined its expression in a range of HCC cell lines and control LX-2 cells. These analyses revealed that TBX19 expression levels were relatively high and low in SNU387 and Huh7 cells, respectively [Figure 2A]. To test the functional relevance of this gene, we then knocked down the TBX19 expresion in SNU387 cells, while upregulating the same in Huh7 cells, using appropriate constructs. As expected, this approach successfully enabled TBX19 knockdown and overexpression in the respective SNU387 and Huh7 cell lines [Figure 2B-C].

Following TBX19 knockdown, SNU387 cell viability was reduced relative to control cells [Figure 3A], as was further confirmed in an EdU uptake assay [Figure 3B]. The migration of these SNU387 cells was also impaired upon TBX19 silencing [Figure 3C-D]

We further constructed a TBX19 overexpression vector [Supplementary Figure 2A], and assessed the localization of TBX19 [Supplementary Figure 2B]. Then, we evaluated its impact on proliferative and migratory activity following successful transfection [Figure 2B-C]. When TBX19 was overexpressed, Huh7 cell viability was enhanced, as were proliferative and migratory activity [Figure 4A-D], thus confirming the ability of this gene to promote these malignant behaviors in tumor cells.


Figure 2.
Figure 2. TBX19 transfection efficiency in HCC cell lines. (A) TBX19 levels were detected via Western blotting in SNU387, LX-2, HepG2, and Huh7 cells. (B) qPCR was used to detect TBX19 expression levels in SNU387 and Huh7 cells. (C) Relative TBX19 levels in SNU387 and Huh7 cells were measured via Western blotting. **P < 0.01 vs. control.


Figure 3.
Figure 3. TBX19 downregulation suppresses HCC cell migration and proliferation in vitro. (A) A CCK-8 assay was employed to assess SNU387 cell proliferation following siR3 transfection. (B) Representative fluorescent images of SNU387 cells following EdU staining, with EdU staining (red) being indicative of proliferation and DAPI (blue) corresponding to cellular nuclei. (C) TBX19 knockdown inhibited SNU387 cell colony formation activity. (D) HCC cell migration was assessed via Transwell assay following TBX19 downregulation, with representative results being shown (100×). **P < 0.01 vs. control.


Figure 4.
Figure 4. TBX19 upregulation enhances in vitro HCC cellular migration and proliferation. (A) A CCK-8 assay was employed to assess Huh7 cell viability following TBX19 overexpression. (B) TBX19 overexpression promoted Huh7 cell proliferation by EdU staining. (C) TBX19 overexpression promoted Huh7 cell colony formation activity. (D) HCC cell migration was assessed via Transwell assay following TBX19 overexpression, with representative results being shown (100×). **P < 0.01 vs. control.


Analysis of TBX19 co-expressed genes in HCC

Next, genes that were co-expressed with TBX19 in HCC tumors were evaluated in an effort to assess patterns of shared genetic risk. In total, 19,922 genes were significantly correlated with TBX19 expression in this oncogenic context, of which 1,731 and 3,585 were respectively positively and negatively correlated with its expression (FDR < 0.01) [Figure 5A]. The top 50 most significantly positively and negatively correlated genes were additionally used to generate heat maps [Supplementary Figure 3]. A GO term enrichment analysis of these TBX19-correlated genes was then conducted, revealing them to be enriched for cellular component terms including nucleus, membrane, and membrane-enclosed lumen, molecular function terms 

including hydrolase activity, nucleic acid binding, ion binding, and protein binding, and biological process terms including response to stimulus, multicellular organismal process, metabolic processes, and biological regulation [Figure 5B]. In a KEGG pathway enrichment analysis, these genes were also enriched in the spliceosome, drug metabolism, tryptophan metabolism, retinol metabolism, and valine, leucine, and isoleucine degradation pathways [Figure 5C]. We elected to focus on DTYMK as a target for further study, as we have previously found it to influence HCC tumor growth and it was more significant than other genes in this context.[28] We subsequently found that TBX19 expression was positively correlated with the expression of DTYMK [Figure 5D]. Overall, these results indicated that TBX19 to play a range of complex regulatory roles in HCC.


Figure 5.
Figure 5. LinkedOmics analysis of the intersection between TBX19 co-expressed genes and TBX19-related differentially expressed genes. (A) TBX19 co-expressed genes within HCC tumors were detected via Spearman correlation analyses using LinkedOmics. (B) Genes correlated with TBX19 expression were subjected to a GO term enrichment analysis of associated cellular component (CC), molecular function (MF), and biological process (BP) terms. (C) Genes correlated with TBX19 expression were subjected to a KEGG pathway enrichment analysis. (D) A positive correlation between TBX19 and DTYMK gene expression was observed. Full results are available online.


TBX19 regulates DTYMK-related dTTP pyrimidine biosynthesis

The DTYMK enzyme plays an essential role in mediating the synthesis of dTTP in pathways associated with pyrimidine metabolism, and poorly differentiated HCC samples exhibit elevated DTYMK expression and the intratumoral concentrations of dTTP.[24] We additionally found that overexpressing TBX19 in Huh7 cells resulted in an increase in dTTP levels within these cells, whereas TBX19 downregulation in TBX19 overexpressing cells was associated with a reduction in these dTTP levels [Figure 6A-B].


Figure 6.
Figure 6. TBX19 promotes DTYMK upregulation and thereby regulates dTTP levels within cells. (A) DTYMK protein expression was assessed within cells following siR3 and/or TBX19 overexpression construct transfection. (B) Relative dTTP levels were measured within cells following siR3 and/or TBX19 overexpression construct transfection. **P < 0.01; Student’s t-tests.


There have been major advances in the management and diagnosis of HCC in recent years. However, early diagnosis rates for this cancer remain unsatisfactory despite the more widespread application of ultrasonography, magnetic resonance imaging, computed tomography, and serum α-fetoprotein-based surveillance.[30] In patients diagnosed with HCC, surgical resection remains the primary treatment approach in combination with radiotherapy, chemotherapy, targeted therapies, interventional therapies, and/or traditional Chinese medicinal treatment as appropriate.[31] However, the prognosis of HCC patients remains poor owing to the high rates of tumor recurrence, with an estimated 5-year survival rate of < 20% for affected patients.[32] There is thus an urgent need to identify potential biomarkers with the potential to improve HCC patient prognostic outcomes.

TBX19, formerly referred to as TPIT, is a gene which encodes a member of the TBX transcription factor family encoding a conserved T-box DNA binding domain. In the first step of our study, we used the UALCAN databases to determine the expression level of TBX19 in cancers and normal tissues. The results showed that TBX19 had significantly higher expression in most cancer types. These results indicated that TBX19 indeed promotes oncogenesis and tumor progression in human cancers. Genes in this family regulate gene expression in essential processes including embryonic development, with TBX19 being capable of binding to specific genes via T-box domain interactions.[33],[34] In mice in which TBX19 is knocked out, a near-total loss of proopiomelanocortin-expressing cells is observed, resulting in profound glucocorticoid and adrenocorticotropic hormone deficiencies.[12],[35],[36],[37]

We then focused on the function of differentially expressed TBX19 using GO enrichment analysis and KEGG pathway enrichment analysis. As expected, we found that the functions of these genes are primarily related to the cellular component terms including nucleus, membrane, and membrane-enclosed lumen, molecular function terms including hydrolase activity, nucleic acid binding and so on. In order to replicate all cells including tumor cells, must be capable of synthesizing and replicating DNA. As such, drugs that disrupt nucleoside metabolism and synthesis are frequently employed to treat certain cancers.[38] In the de novo pathway, deoxyuridine-5’-monophosphate is methylated by thymidylate synthetase to produce deoxythymidine-5’-monophosphate (dTMP),[39] whereas in the salvage pathway thymidine kinase instead phosphorylates thymidine to yield dTMP. In turn, dTMP can be phosphorylated in a reaction catalyzed by deoxythymidylate kinase (DTYMK), thereby yielding dTDP, thus unifying the de novo and salvage pathways and providing an essential basis for the synthesis of additional DNA.[40],[41] In prior reports, DTYMK knockdown was shown to inhibit this pathway, resulting in reduced dTDP levels together with dTMP accumulation.[42]

Here, we found TBX19 to be upregulated at the mRNA level in HCC, with the knockdown of this gene suppressing HCC cell growth and malignancy in vitro, whereas its upregulation had the opposite effect. TBX19 thus appears to play a central role in the context of hepatic oncogenesis, although additional work will be necessary to clarify the molecular mechanisms whereby it shapes tumor progression. Moreover, we found TBX19 protein expression to be correlated with the expression of DTYMK, which regulated dTTP production within HCC tumors. As such, this TBX19 may represent a viable clinical target in HCC patients worthy of future study.

However, there are some limitations to our study. Notably, we did not explore the exact underlying molecular mechanisms and relationship between TBX19 and DTYMK in the context of tumorigenesis, and this will therefore need to be a topic for future research.


In conclusion, these results indicate that TBX19 is overexpressed in HCC tumors and play an important role in the malignancy and progression of this form of cancer. Moreover, we found TBX19 to regulate the expression of DTYMK and associated DTYMK-mediated dTTP production in HCC cells. These findings highlight the HCC effects of TBX19 revealing its potential as a novel therapeutic target for HCC.



This work was supported by the Natural Science Foundations of Shandong Province (No.ZR2021MH022, to Shihai Liu) and the Youth Foundation of Affiliated Hospital of Qingdao University (No.QDFYQN202102025, to Guifang He).



There are no conflicts of interest.



Not applicable.



Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71(1):7-33.


Chen L, Abou-Alfa GK, Zheng B, Liu JF, Bai J, Du LT, Qian YS, Fan R, Liu XL, Wu L, Hou JL, Wang HY, PreCar Team. Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients. Cell Res 2021; 31(5):589-92.


Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60(5):277-300.


Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71(3):209-49.


Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021; 7(1):6.


Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020; 17(3):139-52.


Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019; 16(10):589-604.


Malinee M, Pandian GN, Sugiyama H. Targeted epigenetic induction of mitochondrial biogenesis enhances antitumor immunity in mouse model. Cell Chem Biol 2022; 29(3):463-75.


Hoehner JC, Hedborg F, Wiklund HJ, Olsen L, Påhlman S. Cellular death in neuroblastoma: in situ correlation of apoptosis and bcl-2 expression. Int J Cancer 1995; 62(1):19-24.


Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med 1997; 3(6): 614-20.


Papaioannou VE. The T-box gene family: emerging roles in development, stem cells and cancer. Development 2014; 141(20):3819-33.


Packham EA, Brook JD. T-box genes in human disorders. Hum Mol Genet 2003; 12 Spec No 1:R37-44.


Wansleben S, Peres J, Hare S, Goding CR, Prince S. T-box transcription factors in cancer biology. Biochim Biophys Acta 2014; 1846(2):380-91.


Rowley M, Grothey E, Couch FJ. The role of Tbx2 and Tbx3 in mammary development and tumorigenesis. J Mammary Gland Biol Neoplasia 2004; 9(2):109-18.


Lu J, Li XP, Dong Q, Kung HF, He ML. TBX2 and TBX3: the special value for anticancer drug targets. Biochim Biophys Acta 2010; 1806(2):268-74.


Abrahams A, Parker MI, Prince S. The T-box transcription factor Tbx2: its role in development and possible implication in cancer. IUBMB Life 2010; 62(2):92-102.


Douglas NC, Papaioannou VE. The T-box transcription factors TBX2 and TBX3 in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 2013; 18(2):143-7.


Hansel DE, Rahman A, House M, Ashfaq R, Berg K, Yeo CJ, Maitra A. Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clin Cancer Res 2004; 10(18 Pt 1):6152-8.


Vance KW, Carreira S, Brosch G, Goding CR. Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas. Cancer Res 2005; 65(6): 2260-8.


Ando J, Saito M, Imai JI, Ito E, Yanagisawa Y, Honma R, Saito K, Tachibana K, Momma T, Ohki S, Ohtake T, Watanabe S, Waguri S, Kono K, Takenoshita S. TBX19 is overexpressed in colorectal cancer and associated with lymph node metastasis. Fukushima J Med Sci 2017; 63(3):141-51.


Chen YF, Wang JY, Wu CH, Chen FM, Cheng TL, Lin SR. Detection of circulating cancer cells with K-ras oncogene using membrane array. Cancer Lett 2005; 229(1):115-22.


Zhou T, Qin R, Shi S, Zhang H, Niu C, Ju G, Miao S. DTYMK promote hepatocellular carcinoma proliferation by regulating cell cycle. Cell Cycle 2021; 20(17):1681-91.


Guo Y, Luo W, Huang S, Zhao W, Chen H, Ma Y, Ye M, Nie Y, Zhang Y, Huang C, Zhou Q, He X, Chen M. DTYMK Expression Predicts Prognosis and Chemotherapeutic Response and Correlates with Immune Infiltration in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021; 8:871-85.


Yeh HW, Lee SS, Chang CY, Hu CM, Jou YS. Pyrimidine metabolic rate limiting enzymes in poorly-differentiated hepatocellular carcinoma are signature genes of cancer stemness and associated with poor prognosis. Oncotarget 2017; 8(44):77734-51.


Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia 2017; 19(8):649-58.


Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25(4):402-8.


Liu S, Qiu J, He G, He W, Liu C, Cai D, Pan H. TRAIL promotes hepatocellular carcinoma apoptosis and inhibits proliferation and migration via interacting with IER3. Cancer Cell Int 2021; 21(1):63.


He G, Qiu J, Liu C, Tian B, Cai D, Liu S. MiR-148b-3p Regulates the Expression of DTYMK to Drive Hepatocellular Carcinoma Cell Proliferation and Metastasis. Front Oncol 2021; 11:625566.


Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res 2018; 46(D1):D956-63.


Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee AK, Singal AG. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154(6):1706-18.


Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ 2020; 371:m3544.


Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology 2019; 156(2):477-91.


Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, Reese D, Wiezorek J, Blackhall F. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 2010; 28(9):1527-33.


Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16(17):5386-97.


Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, Enjalbert A, Drouin J. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 2001; 104(6):849-59.


Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, Smith CA. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186(7):1165-70.


Kelberman D, Rizzoti K, Lovell-Badge R, Robinson IC, Dattani MT. Genetic regulation of pituitary gland development in human and mouse. Endocr Rev 2009; 30(7):790-829.


Kohnken R, Kodigepalli KM, Wu L. Regulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications. Mol Cancer 2015; 14:176.


Van Triest B, Pinedo HM, Giaccone G, Peters GJ. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 2000; 11(4):385-91.


Reichard P. Interactions between deoxyribonucleotide and DNA synthesis. Annu Rev Biochem 1988; 57:349-74.


Arnér ES, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther 1995; 67(2): 155-86.


Liu Y, Marks K, Cowley GS, Carretero J, Liu Q, Nieland TJ, Xu C, Cohoon TJ, Gao P, Zhang Y, Chen Z, Altabef AB, Tchaicha JH, Wang X, Choe S, Driggers EM, Zhang J, Bailey ST, Sharpless NE, Hayes DN, Patel NM, Janne PA, Bardeesy N, Engelman JA, Manning BD, Shaw RJ, Asara JM, Scully R, Kimmelman A, Byers LA, Gibbons DL, Wistuba II, Heymach JV, Kwiatkowski DJ, Kim WY, Kung AL, Gray NS, Root DE, Cantley LC, Wong KK. Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov 2013; 3(8):870-9.




Supplementary Figure 1.
Supplementary Figure 1. Gene expression profiles for all tumors and paired normal tissue samples included in the UALCAN database.

Supplementary Figure 2.
Supplementary Figure 2. TBX19 vector construct preparation, sequencing, and localization analyses. (A) The constructed TBX19 overexpression vector. (B) Immunofluorescent assessment of TBX19 localization within Huh7 cells (red), with DAPI (blue) being used for nuclear counterstaining.

Supplementary Figure 3.
Supplementary Figure 3. LinkedOmics analysis of the intersection between TBX19 co-expressed genes and TBX19-related differentially expressed genes. (A) The top 50 genes that were positively correlated with the expression of TBX19 within HCC tumors as assessed via LinkedOmics. (B) The top 50 genes that were negatively correlated with the expression of TBX19 within HCC tumors as assessed via LinkedOmics. Green and red respectively correspond to genes negatively and positively correlated with the expression of TBX19.



This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution‑NonCommercial‑ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non‑commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact:


All claims made in this article are exclusively those of the writers, and do not necessarily reflect the views of their connected organizations, the publisher, editors, or reviewers. The publication does not guarantee or promote any product that may be evaluated in this article or any claim made by its producer.

Related Articles

TRAF Proteins In NSCLC: Analysis Of Data From The Public Database And Literature Review

Xuebing Li1, Yaguang Fan1, Hongli Pan1, Yang Li1, Limin Cao1, Zhenhua Pan1, Lingling Zu1, Fanrong Meng2, Mengjie Li3, Qinghua Zhou1, Xuexia Zhou4*


Research Progress of Cytokines and Their Receptors in Ovarian Cancer

Yuanwen Zhang1, Zhouman He1, Shiyun Liang1, Jian Yuan1, Huihui Ti1 *



Contribution Of Human Endogenous Retroviruses To Metastasis Of Solid Tumors

Nianbin Li1, Jing Wang2, Yaguang Fan2, Min Wang2, Chen Chen2, Ting Wang1*, Heng Wu2*



Role of PD-1/PD-L1 Inhibitors in the Treatment of Metastatic Lung Cancer

Yufei Chen1, Mei Zhong2, Zhenhua Pan2, Jun Chen2, Hongli Chen2, Fengjie Guo2, 3,*



Cytochrome P450 2C19 Polymorphisms are Associated with a High Risk of Esophageal Squamous Cell Carcinoma in Asian Populations: A Systematic Review and Meta-Analysis

Xuehan Gao1, Zhihong Qian2, Guige Wang1, Lei Liu1, Jiaqi Zhang1, Ke Zhao1, Mengxin Zhou1, Shanqing Li1*

Limb Arterial Embolism secondary to Myocardial Primary Light Chain Amyloidosis – A Case Report

Lei Ji1, Zhili Liu1, Yuehong Zheng1*

In situ Laser Fenestration to Reconstruct Three Supra Arch Branches for Recurrent Aortic Dissection after Replacement of the Ascending Aorta and Implantation of Stent Graft in the Descending Aorta: A Case Report

Li Yuan Niu1, Hai Xin1, Hao Fu Wang1*, Yue Wei Wang1*

Research progress in traditional Chinese medicine for the treatment of androgenic alopecia

Weiwei LI1, Chenghao Zhu2, Dandan Yang3, Yanhua YI1, Shuncai Liu1, Zhenyu Gong1*

Isolated Abdominal Wall Metastasis without Definitive Primary Lesion after Laparoscopic Cholecystectomy: A Case Report

La Zhang1, Ning Jiang2, Rui Liao1, Baoyong Zhou1*, Dewei Li3*

Analysis of Immune-Related Genes in the Tumor Microenvironment of Bladder Cancer based on TCGA database

Haiyang Jiang1#, Longguo Dai1#, Huijian Wang1#, Chongjian Zhang1, Yu Bai1, Ruiqian Li1, Jun Li1, Chen Hu1, Hongyi Wu1, Hong Yang1, Qilin Wang1, Pingting Chen2*

Diagnostic Biomarkers in Cerebrospinal Fluid in Primary Central Nervous System Lymphoma: A Protocol for Systematic Review and Meta-analysis

Lili Zhou1,2, Hai Yi1*, Dan Chen1, Qian Zhang1, Fangyi Fan1, Ling Qiu1, Nan Zhang1, Yi Su1

Updates on Molecular Markers for Gliomas

Jingyao Jie1, Weijuan Zhang2*

Peroxisome Proliferator-Activated Receptor-γ Agonists as New Targets of Lung Cancer Therapy

Shixiong Wei1*

Microcirculation Specialist Consensus on Diagnosis and Treatment of Superficial Varicose Veins of Lower Limbs

Wang Lei1, Zheng Yuehong1*

Anticoagulation might not be necessary for asymptomatic central venous catheter-related thrombosis in adults

Wei Zhang1, Zhi Xiang1, Qin Ma2, Chuanlin Zhang3, Yu Zhao1, Qining Fu1*

The Roles of microRNA in the Diagnosis and Prognosis of Papillary Thyroid Cancer

Jingya Gao1*, Li Liu2*

Lung Cancer Tumor Microenvironment: An Update on Recent Advances in Research

Guangda Yuan1, Bowen Hu1, Yong Yang1*

Quantified ADC Values and Attenuation Trends for Diagnosing Prostate Cancer with Multiple b Values MRI

Jing Hu1#, Jingying Bu1#,Zhe Wang2#, Zhengdan Su2, Xiaoxian Wang2, Haiyao Pi3, Diliang Li2, Zhaoyang Pu4, Xin Tian1*

Advances in Pathogenesis and Non-surgical Therapy of Cutaneous Basal Cell Carcinoma

Yichen Wu1, Jia Chen2*

Quercetin Inhibits the Proliferation and Migration of Pancreatic Adenocarcinoma by Targeting the Prognostic-related Gene MMP1 via Bioinformatics and Network Pharmacology

Zhenhua Zu1,2#, Zhongguo Zhu3#, Zhiyu Xia2, Hongrang Chen1*, Yongsheng Li1*

Huge Lung Fibroleiomyomatous Hamartoma in the Pleural Cavity – A Case report

Minghui Liu1#, Xin Li1#, Hongbing Zhang1, Fan Ren1, Ming Dong1, Chunqiu Xia1, Jun Chen1,2*

Increased Expression of IL-17A, IL-6, STAT3, TGF-β, and VEGF: Potential Biomarkers in Bladder Cancer?

Zishen Xiao1, Chengxia Bai1, Teng Zhao1, Jiayu Lin1, Lijuan Yang1, Jian Liu2, Zhenjiang Wang1, Ying Sun3,4, Yanbo Liu1*

Identification of NSD2 as a Potential Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma

Wei Zhao1#, Xinyu Xiao1#, Yu Gao1,2, Shanshan Liu3, Xiuzhen Zhang1, Changhong Yang1, Qiling Peng1, Ning Jiang2*, Jianwei Wang1*

Quercetin Inhibits Glioma Proliferation by Targeting CDK1 and CCNB1 - Bioinformatics and Network Pharmacology

Huaixu Li1#, Peng Gao1#, Haotian Tian1, Zhenyu Han2, Xingliang Dai1*, Hongwei Cheng1*

Selective Internal Radiation Therapy with Yttrium-90 Microspheres in Hepatocellular Carcinoma – Applications and recent advances

Wei Wang1, Dawei Xie1, Bing Li1, Minghao Chen1*

Irreversible Electroporation in Pancreatic Cancer – Applications and recent advances

Yuanyuan Sun1, Qian Li2, Jia Hu2, Yanfang Liu2*, Xiaosong Li2*

Prognostic Value of Bismuth Typing and Modified T‑stage in Hilar Cholangiocarcinoma

Shengen Yi, Xiongjian Cui, Li Xiong, Xiaofeng Deng, Dongni Pei, Yu Wen, Xiongying Miao

MicroRNAs are Related to Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Resistance in Patients with Diffuse Large B-cell Lymphoma

Haibo Huang1, Junjiao Gu1, Shuna Yao1, Zhihua Yao1, Yan Zhao1, Qingxin Xia2, Jie Ma2, Ling Mai3, Shujun Yang1, Yanyan Liu1

Comparison of Intra-voxel Incoherent Motion Diffusion Magnetic Resonance Imaging and Apparent Diffusion Coefficient in the Evaluation of Focal Malignant Liver Masses

Jinrong Qu1, Xiang Li1, Lei Qin2, Lifeng Wang1, Junpeng Luo1, Jianwei Zhang1, Hongkai Zhang1, Jing Li1, Fei Sun3, Shouning Zhang1, Yanle Li1, Cuicui Liu1, Hailiang Li1

Extracting Breathing Signal Using Fourier Transform from Cine Magnetic Resonance Imaging

Jing Cai1,2, Yilin Liu2, Fangfang Yin1,2

Split End Family RNA Binding Proteins: Novel Tumor Suppressors Coupling Transcriptional Regulation with RNA Processing

Hairui Su1, Yanyan Liu2, Xinyang Zhao1

Thioredoxin-interacting Protein as a Common Regulation Target for Multiple Drugs in Clinical Therapy/Application

Pengxing  Zhang1, Xiaoling Pang2,3, Yanyang Tu1,4

Associations of Age and Chemotherapy with Late Skin and Subcutaneous Tissue Toxicity in a Hypofractionated Adjuvant Radiation Therapy Schedule in Post‑mastectomy Breast Cancer Patients

Mohammad Akram1, Ghufran Nahid1, Shahid Ali Siddiqui1, Ruquiya Afrose2

Monitoring of Disease Activity in Chronic Myeloid Leukemia‑chronic Phase Patients Treated with Indian Generic Veenat (NATCO) Imatinib Mesylate: A Tertiary Care Experience

Khushboo Dewan, Tathagat Chatterjee

Review of Cancer Immunotherapy: Application of Chimeric Antigen Receptor T Cells and Programmed Death 1/Programmed Death‑ligand 1 Antibodies

Tengfei Zhang1,2, Ling Cao1, Zhen Zhang1, Dongli Yue1, Yu Ping1, Hong Li1, Lan Huang1, Yi Zhang1,3,4,5

Systematic Review of MicroRNAs and its Therapeutic Potential in Glioma

Nan Liu1, Yanyang Tu2

The Involvement of p53‑miR‑34a‑CDK4 Signaling During the Development of Cervical Cancer

Huijun Zuo, Jieqi Xiong, Hongwei Chen, Sisun Liu, Qiaoying Gong, Fei Guo

Unusual Clinical Presentation of a Rare Type of Breast Malignancy: A Case Report and a Short Review of Literature

Nadeesha J. Nawarathna1, Navam R. Kumarasinghe1, Palitha Rathnayake2,
Ranjith J. K. Seneviratne1

Sweet’s Syndrome in Acute Lymphoblastic Leukemia with t (9:22)

Khushboo Dewan, Shailaja Shukla

Analysis of the Correlationship between Prostate Specific Antigen Related Variables and Risk Factor in Patients with Prostate Carcinoma

Daoyuan Wang1, Tiejun Yang2, Yongqiang Zou1, Xinqiang Yang1

Recent Progress in Genetic and Epigenetic Profile of Diffuse Gastric Cancer

Zhengxi He1, Bin Li1,2

Strategies for Management of Spinal Metastases: A Comprehensive Review

Zhantao Deng, Bin Xu, Jiewen Jin, Jianning Zhao, Haidong Xu

Application and Perspectives of Traditional Chinese Medicine in the Treatment of Liver Cancer

Xia Mao, Yanqiong Zhang, Na Lin

Primary Hepatic Carcinoid Tumor: A Case Report and Literature Review

Yupeng Lei1, Hongxia Chen2, Pi Liu1, Xiaodong Zhou1

Expression Characteristics of miR‑10b in Nasopharyngeal Carcinoma

Gang Li, Yunteng Zhao, Jianqi Wang, Haoran Huang, Mengwen Zhang

An Update on Immunohistochemistry in Translational Cancer Research

Zonggao Shi, M. Sharon Stack

Promoter Methylated Tumor Suppressor Genes in Glioma

Yingduan Cheng1, Yanyang Tu2, Pei Liang3

Palliative Treatment of Malignant Pleural Effusion

Chenyang Liu1*, Qian Qian2*, Shen Geng1, Wenkui Sun1, Yi Shi1

Functional Perspective and Implications of Gene Expression by Noncoding RNAs

Xiaoshuang Yan1, Huanyu Xu2, Zhonghai Yan3

Expression of E3 Ubiquitin Ligases in Multiple Myeloma Patients after Treatment with the Proteasome Inhibitor Bortezomib

James Joseph Driscoll

miR‑505 Downregulates 6‑Phosphofructo‑2‑Kinase/ Fructose‑2,6‑Biphosphatase 4 to Promote Cell Death in Glioblastoma

Esther H. Chung, Hongwei Yang, Hongyan Xing, Rona S. Carroll, Mark D. Johnson

Utility of Fine Needle Aspiration Cytology in Diagnosing Bone Tumors

Sonal Mahajan1, Akash Arvind Saoji2, Anil Agrawal1

Histone H2A and H2B Deubiquitinase in Developmental Disease and Cancer

Demeng Chen1, Caifeng Dai2, Yizhou Jiang3

Genetic Characteristics of Glioblastoma: Clinical Implications of Heterogeneity

Qian Li1, Yanyang Tu1,2

Acute Lymphoblastic Leukemia with Normal Platelet Count

Khushboo Dewan, Kiran Agarwal

Galanin is a Novel Epigenetic Silenced Functional Tumor Suppressor in Renal Cell Carcinoma

Shengkun Sun1*, Axiang Xu1*, Guoqiang Yang1, Yingduan Cheng2


Selenium Dioxide Induced Apoptosis in Cervical Cancer Cells via Regulating Apoptosis-related Let-7a MicroRNA and Proteins

Sisun Liu1, Jieqi Xiong2, Ling Guo3, Min Xiu1,4, Feng He1,4, Yuanlei Lou5, Fei Guo6,7

Low Expression of Polo‑like Kinase 1 is Associated with Poor Prognosis in Liver Cancer

Weixia Li1, Kunpeng Liu1, Dechen Lin2, Xin Xu2, Haizhen Lu3, Xinyu Bi4, Mingrong Wang2

Extracorporeal Photopheresis for Steroid‑refractory Chronic Graft‑versus‑host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta‑Analysis

Runzhe Chen1, Baoan Chen1, Peter Dreger2, Michael Schmitt2, Anita Schmitt2

Glucans and Cancer: Historical Perspective

Petr Sima1, Luca Vannucci1, Vaclav Vetvicka2

Implications of Circadian Rhythm Regulation by microRNAs in Colorectal Cancer

Song Wu1, Andrew Fesler2, Jingfang Ju2

BCL2 Family, Mitochondrial Apoptosis, and Beyond

Haiming Dai1, X. Wei Meng2, Scott H. Kaufmann2

Quantum Dot‑based Immunohistochemistry for Pathological Applications

Li Zhou1, Jingzhe Yan2, Lingxia Tong3, Xuezhe Han4, Xuefeng Wu5, Peng Guo6

CD24 as a Molecular Marker in Ovarian Cancer: A Literature Review

Lu Huang1, Weiguo Lv2, Xiaofeng Zhao1

Etiological Trends in Oral Squamous Cell Carcinoma: A Retrospective Institutional Study

Varsha Salian, Chethana Dinakar, Pushparaja Shetty, Vidya Ajila

Effect of Irinotecan Combined with Cetuximab on Liver Function in Patients with Advanced Colorectal Cancer with Liver Metastases

Yan Liang1, Yang Li2, Xin Li3, Jianfu Zhao4

The Role of Precision Medicine in Pancreatic Cancer: Challenges for Targeted Therapy, Immune Modulating Treatment, Early Detection, and Less Invasive Operations

Khaled Kyle Wong1, Zhirong Qian2, Yi Le3

Targeting Signal Transducer and Activator of Transcription 3 for Colorectal Cancer Prevention and Treatment with Natural Products

Weidong Li1,2*, Cihui Chen3*, Zheng Liu2, Baojin Hua1

The Potential of Wnt Signaling Pathway in Cancer: A Focus on Breast Cancer

Mahnaz M. Kazi, Trupti I. Trivedi, Toral P. Kobawala, Nandita R. Ghosh

Imaging‑driven Digital Biomarkers

Enrico Capobianco

Target‑Matching Accuracy in Stereotactic Body Radiation Therapy of Lung Cancer: An Investigation Based on Four‑Dimensional Digital Human Phantom

Jing Cai1,2, Kate Turner2, Xiao Liang2, W. Paul Segars2,3, Chris R. Kelsey1, David Yoo1, Lei Ren1,2, Fang‑Fang Yin1,2

Downregulation of Death‑associated Protein Kinase 3 and Caspase‑3 Correlate to the Progression and Poor Prognosis of Gliomas

Ye Song, Tianshi Que, Hao Long, Xi’an Zhang, Luxiong Fang, Zhiyong Li, Songtao Qi

Hyaluronic Acid in Normal and Neoplastic Colorectal Tissue: Electrospray Ionization Mass Spectrometric and Fluor Metric Analysis

Ana Paula Cleto Marolla1, Jaques Waisberg2, Gabriela Tognini Saba2, Demétrius Eduardo Germini2, Maria Aparecida da Silva Pinhal1

Melanoma Antigen Gene Family in the Cancer Immunotherapy

Fengyu Zhu1, Yu Liang1, Demeng Chen2, Yang Li1

Combined Chronic Lymphocytic Leukemia and Pancreatic Neuroendocrine Carcinoma: A Collision Tumor Variation

Kaijun Huang1, Panagiotis J. Vlachostergios1, Wanhua Yang2, Rajeev L. Balmiki3

Antiproliferative and Apoptotic Effect of Pleurotus ostreatus on Human Mammary Carcinoma Cell Line (Michigan Cancer Foundation‑7)

Krishnamoorthy Deepalakshmi, Sankaran Mirunalini

Impact of Age on the Biochemical Failure and Androgen Suppression after Radical Prostatectomy for Prostate Cancer in Chilean Men

Nigel P. Murray1,2, Eduardo Reyes1,3, Nelson Orellana1, Cynthia Fuentealba1, Omar Jacob1

Carcinoma of Unknown Primary: 35 Years of a Single Institution’s Experience

Rana I. Mahmood1,2, Mohammed Aldehaim1,3, Fazal Hussain4, Tusneem A. Elhassan4,
Zubeir A. Khan5, Muhammad A. Memon6

Metformin in Ovarian Cancer Therapy: A Discussion

Yeling Ouyang1, Xi Chen2, Chunyun Zhang1, Vichitra Bunyamanop1, Jianfeng Guo3

The Progress in Molecular Biomarkers of Gliomas

Jing Qi1, Hongwei Yang2, Xin Wang2, Yanyang Tu1

Correlation between Paclitaxel Tc > 0.05 and its Therapeutic Efficacy and Severe Toxicities in Ovarian Cancer Patients

Shuyao Zhang1*, Muyin Sun2*, Yun Yuan3*, Miaojun Wang4*, Yuqi She1*, Li Zhou5, Congzhu Li5, Chen Chen1, Shengqi Zhang4

Identifying Gaps and Relative Opportunities for Discovering Membrane Proteomic Biomarkers of Triple‑negative Breast Cancer as a Translational Priority

Bhooma Venkatraman

The Molecular Mechanism and Regulatory Pathways of Cancer Stem Cells

Zhen Wang1, Hongwei Yang2, Xin Wang2, Liang Wang3, Yingduan Cheng4, Yongsheng Zhang5, Yanyang Tu1,2

Nanoparticle Drug Delivery Systems and Three‑dimensional Cell Cultures in Cancer Treatments and Research

Wenjin Shi1, Ding Weng2,3, Wanting Niu2,3

Choline Kinase Inhibitors Synergize with TRAIL in the Treatment of Colorectal Tumors and Overcomes TRAIL Resistance

Juan Carlos Lacal1, Ladislav Andera2

MicroRNA Regulating Metabolic Reprogramming in Tumor Cells: New Tumor Markers

Daniel Otero‑Albiol, Blanca Felipe‑Abrio

Biomarkers of Colorectal Cancer: A Genome‑wide Perspective

José M. Santos‑Pereira1, Sandra Muñoz‑Galván2

Nicotinamide Adenine Dinucleotide+ Metabolism Biomarkers in Malignant Gliomas

Manuel P. Jiménez‑García, Eva M. Verdugo‑Sivianes, Antonio Lucena‑Cacace

Patient-derived Xenografts as Models for Personalized Medicine Research in Cancer

Marco Perez, Lola Navas, Amancio Carnero

Genome‑wide Transcriptome Analysis of Prostate Cancer Tissue Identified Overexpression of Specific Members of the Human Endogenous Retrovirus‑K Family

Behnam Sayanjali1,2

Clinical Utility of Interleukin‑18 in Breast Cancer Patients: A Pilot Study

Reecha A. Parikh, Toral P. Kobawala, Trupti I. Trivedi, Mahnaz M. Kazi, Nandita R. Ghosh

Current and Future Systemic Treatment Options for Advanced Soft‑tissue Sarcoma beyond Anthracyclines and Ifosfamide

Nadia Hindi1,2, Javier Martin‑Broto1,2

The Genomic Organization and Function of IRX1 in Tumorigenesis and Development

Pengxing Zhang1, Hongwei Yang2, Xin Wang2, Liang Wang3, Yingduan Cheng4, Yongsheng Zhang5, Yanyang Tu1,2

Stem Cell‑based Approach in Diabetes and Pancreatic Cancer Management

Yi‑Zhou Jiang1, Demeng Chen2

Mutation Detection with a Liquid Biopsy 96 Mutation Assay in Cancer Patients and Healthy Donors

Aaron Yun Chen, Glenn D. Braunstein, Megan S. Anselmo, Jair A. Jaboni, Fernando Troy Viloria, Julie A. Neidich, Xiang Li, Anja Kammesheidt

The Application of Estrogen Receptor‑1 Mutations’ Detection through Circulating Tumor DNA in Breast Cancer

Binliang Liu, Yalan Yang, Zongbi Yi, Xiuwen Guan, Fei Ma

Circulating MicroRNAs and Long Noncoding RNAs: Liquid Biomarkers in Thoracic Cancers

Pablo Reclusa1, Anna Valentino1, Rafael Sirera1,2, Martin Frederik Dietrich3, Luis Estuardo Raez3, Christian Rolfo1

Exosomes Biology: Function and Clinical Implications in Lung Cancer

Martin Frederik Dietrich1, Christian Rolfo2, Pablo Reclusa2, Marco Giallombardo2, Anna Valentino2, Luis E. Raez1

Circulating Tumor DNA: A Potential Biomarker from Solid Tumors’ Monitor to Anticancer Therapies

Ting Chen1,2, Rongzhang He1,3, Xinglin Hu1,3,4, Weihao Luo1, Zheng Hu1,3, Jia Li1, Lili Duan1, Yali Xie1,2, Wenna Luo1,2, Tan Tan1,2, Di‑Xian Luo1,2

Novel Molecular Multilevel Targeted Antitumor Agents

Poonam Sonawane1, Young A. Choi1, Hetal Pandya2, Denise M. Herpai1, Izabela Fokt3,
Waldemar Priebe3, Waldemar Debinski1

Fish Oil and Prostate Cancer: Effects and Clinical Relevance

Pei Liang, Michael Gao Jr.

Stemness‑related Markers in Cancer

Wenxiu Zhao1, Yvonne Li2, Xun Zhang1

Autophagy Regulated by miRNAs in Colorectal Cancer Progression and Resistance

Andrew Fesler1, Hua Liu1, Ning Wu1,2, Fei Liu3, Peixue Ling3, Jingfang Ju1,3

Gastric Metastases Mimicking Primary Gastric Cancer: A Brief Literature Review

Simona Gurzu1,2,3, Marius Alexandru Beleaua1, Laura Banias2, Ioan Jung1

Possibility of Specific Expression of the Protein Toxins at the Tumor Site with Tumor‑specialized Promoter

Liyuan Zhou1,2, Yujun Li1,2, Changchen Hu3, Binquan Wang1,2

SKI‑178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models

Jeremy A. Hengst1,2, Taryn E. Dick1,2, Arati Sharma1, Kenichiro Doi3, Shailaja Hegde4, Su‑Fern Tan5, Laura M. Geffert1,2, Todd E. Fox5, Arun K. Sharma1, Dhimant Desai1, Shantu Amin1, Mark Kester5, Thomas P. Loughran5, Robert F. Paulson4, David F. Claxton6, Hong‑Gang Wang3, Jong K. Yun1,2

A T‑cell Engager‑armed Oncolytic Vaccinia Virus to Target the Tumor Stroma

Feng Yu1, Bangxing Hong1, Xiao‑Tong Song1,2,3

Real‑world Experience with Abiraterone in Metastatic Castration‑resistant Prostate Cancer

Yasar Ahmed1, Nemer Osman1, Rizwan Sheikh2, Sarah Picardo1, Geoffrey Watson1

Combination of Interleukin‑11Rα Chimeric Antigen Receptor T‑cells and Programmed Death‑1 Blockade as an Approach to Targeting Osteosarcoma Cells In vitro

Hatel Rana Moonat, Gangxiong Huang, Pooja Dhupkar, Keri Schadler, Nancy Gordon,
Eugenie Kleinerman

Efficacy and Safety of Paclitaxel‑based Therapy and Nonpaclitaxel‑based Therapy in Advanced Gastric Cancer

Tongwei Wu, Xiao Yang, Min An, Wenqin Luo, Danxian Cai, Xiaolong Qi

Motion Estimation of the Liver Based on Deformable Image Registration: A Comparison Between Four‑Dimensional‑Computed Tomography and Four‑Dimensional-Magnetic Resonance Imaging

Xiao Liang1, Fang‑Fang Yin1,2, Yilin Liu1, Brian Czito2, Manisha Palta2, Mustafa Bashir3, Jing Cai1,2

A Feasibility Study of Applying Thermal Imaging to Assist Quality Assurance of High‑Dose Rate Brachytherapy

Xiaofeng Zhu1, Yu Lei1, Dandan Zheng1, Sicong Li1, Vivek Verma1, Mutian Zhang1, Qinghui Zhang1, Xiaoli Tang2, Jun Lian2, Sha X. Chang2, Haijun Song3, Sumin Zhou1, Charles A. Enke1

Role of Exosome microRNA in Breast Cancer

Wang Qu, Ma Fei, Binghe Xu

Recent Progress in Technological Improvement and Biomedical Applications of the Clustered Regularly Interspaced Short Palindromic Repeats/Cas System

Yanlan Li1,2*, Zheng Hu1*, Yufang Yin3, Rongzhang He1, Jian Hu1, Weihao Luo1, Jia Li1, Gebo Wen2, Li Xiao1, Kai Li1, Duanfang Liao4, Di-Xian Luo1,5

The Significance of Nuclear Factor‑Kappa B Signaling Pathway in Glioma: A Review

Xiaoshan Xu1, Hongwei Yang2, Xin Wang2, Yanyang Tu1

Markerless Four‑Dimensional‑Cone Beam Computed Tomography Projection‑Phase Sorting Using Prior Knowledge and Patient Motion Modeling: A Feasibility Study

Lei Zhang1,2, Yawei Zhang2, You Zhang1,2,3, Wendy B. Harris1,2, Fang‑Fang Yin1,2,4, Jing Cai1,4,5, Lei Ren1,2

The Producing Capabilities of Interferon‑g and Interleukin‑10 of Spleen Cells in Primary and Metastasized Oral Squamous Cell Carcinoma Cells-implanted Mice

Yasuka Azuma1,2, Masako Mizuno‑Kamiya3, Eiji Takayama1, Harumi Kawaki1, Toshihiro Inagaki4, Eiichi Chihara2, Yasunori Muramatsu5, Nobuo Kondoh1

“Eating” Cancer Cells by Blocking CD47 Signaling: Cancer Therapy by Targeting the Innate Immune Checkpoint

Yi‑Rong Xiang, Li Liu

Glycosylation is Involved in Malignant Properties of Cancer Cells

Kazunori Hamamura1, Koichi Furukawa2

Biomarkers in Molecular Epidemiology Study of Oral Squamous Cell Carcinoma in the Era of Precision Medicine

Qing‑Hao Zhu1*, Qing‑Chao Shang1*, Zhi‑Hao Hu1*, Yuan Liu2, Bo Li1, Bo Wang1, An‑Hui Wang1

I‑Kappa‑B Kinase‑epsilon Activates Nuclear Factor‑kappa B and STAT5B and Supports Glioblastoma Growth but Amlexanox Shows Little Therapeutic Potential in These Tumors

Nadège Dubois1, Sharon Berendsen2, Aurélie Henry1,2, Minh Nguyen1, Vincent Bours1,
Pierre Alain Robe1,2

Suppressive Effect of Mesenchymal Stromal Cells on Interferon‑g‑Producing Capability of Spleen Cells was Specifically Enhanced through Humoral Mediator(s) from Mouse Oral Squamous Cell Carcinoma Sq‑1979 Cells In Vitro

Toshihiro Inagaki1,2, Masako Mizuno‑Kamiya3, Eiji Takayama1, Harumi Kawaki1, Eiichi Chihara4, Yasunori Muramatsu5, Shinichiro Sumitomo5, Nobuo Kondoh1

An Interplay Between MicroRNA and SOX4 in the Regulation of Epithelial–Mesenchymal Transition and Cancer Progression

Anjali Geethadevi1, Ansul Sharma2, Manish Kumar Sharma3, Deepak Parashar1

MicroRNAs Differentially Expressed in Prostate Cancer of African‑American and European‑American Men

Ernest K. Amankwah

The Role of Reactive Oxygen Species in Screening Anticancer Agents

Xiaohui Xu1, Zilong Dang2, Taoli Sun3, Shengping Zhang1, Hongyan Zhang1

Panobinostat and Its Combination with 3‑Deazaneplanocin‑A Induce Apoptosis and Inhibit In vitro Tumorigenesis and Metastasis in GOS‑3 Glioblastoma Cell Lines

Javier de la Rosa*, Alejandro Urdiciain*, Juan Jesús Aznar‑Morales, Bárbara Meléndez1,
Juan A. Rey2, Miguel A. Idoate3, Javier S. Castresana

Cancer Stem‑Like Cells Have Cisplatin Resistance and miR‑93 Regulate p21 Expression in Breast Cancer

Akiko Sasaki1, Yuko Tsunoda2, Kanji Furuya3, Hideto Oyamada1, Mayumi Tsuji1, Yuko Udaka1, Masahiro Hosonuma1, Haruna Shirako1, Nana Ichimura1, Yuji Kiuchi1

The Contribution of Hexokinase 2 in Glioma

Hui Liu1, Hongwei Yang2, Xin Wang3, Yanyang Tu1

The Mechanism of BMI1 in Regulating Cancer Stemness Maintenance, Metastasis, Chemo‑ and Radiation Resistance

Xiaoshan Xu, Zhen Wang, Nan Liu, Pengxing Zhang, Hui Liu, Jing Qi, Yanyang Tu

A Multisource Adaptive Magnetic Resonance Image Fusion Technique for Versatile Contrast Magnetic Resonance Imaging

Lei Zhang1,2, Fang‑Fang Yin1,2,3, Brittany Moore1,2, Silu Han1,2, Jing Cai1,2,4

Senescence and Cancer

Sulin Zeng1,2, Wen H. Shen2, Li Liu1

The “Wild”‑type Gastrointestinal Stromal Tumors: Heterogeneity on Molecule Characteristics and Clinical Features

Yanhua Mou1, Quan Wang1, Bin Li1,2

Retreatment with Cabazitaxel in a Long‑Surviving Patient with Castration‑Resistant Prostate Cancer and Visceral Metastasis

Raquel Luque Caro, Carmen Sánchez Toro, Lucia Ochoa Vallejo

Therapy‑Induced Histopathological Changes in Breast Cancers: The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment

Shazima Sheereen1, Flora D. Lobo1, Waseemoddin Patel2, Shamama Sheereen3,
Abhishek Singh Nayyar4, Mubeen Khan5

Glioma Research in the Era of Medical Big Data

Feiyifan Wang1, Christopher J. Pirozzi2, Xuejun Li1

Transarterial Embolization for Hepatocellular Adenomas: Case Report and Literature Review

Jian‑Hong Zhong1,2, Kang Chen1, Bhavesh K. Ahir3, Qi Huang4, Ye Wu4, Cheng‑Cheng Liao1, Rong‑Rong Jia1, Bang‑De Xiang1,2, Le‑Qun Li1,2

Nicotinamide Phosphoribosyltransferase: Biology, Role in Cancer, and Novel Drug Target

Antonio Lucena‑Cacace1,2,3, Amancio Carnero1,2

Enhanced Anticancer Effect by Combination of Proteoglucan and Vitamin K3 on Bladder Cancer Cells

Michael Zhang, Kelvin Zheng, Muhammad Choudhury, John Phillips, Sensuke Konno

Molecular Insights Turning Game for Management of Ependymoma: A Review of Literature

Ajay Sasidharan, Rahul Krishnatry

IDH Gene Mutation in Glioma

Leping Liu1, Xuejun Li1,2

Challenges and Advances in the Management of Pediatric Intracranial Germ Cell Tumors: A Case Report and Literature Review

Gerard Cathal Millen1, Karen A. Manias1,2, Andrew C. Peet1,2, Jenny K. Adamski1

Assessing the Feasibility of Using Deformable Registration for Onboard Multimodality‑Based Target Localization in Radiation Therapy

Ge Ren1,2,3, Yawei Zhang1,2, Lei Ren1,2

Research Advancement in the Tumor Biomarker of Hepatocellular Carcinoma

Qing Du1, Xiaoying Ji2, Guangjing Yin3, Dengxian Wei3, Pengcheng Lin1, Yongchang Lu1,
Yugui Li3, Qiaohong Yang4, Shizhu Liu5, Jinliang Ku5, Wenbin Guan6, Yuanzhi Lu7

Novel Insights into the Role of Bacterial Gut Microbiota in Hepatocellular Carcinoma

Lei Zhang1, Guoyu Qiu2, Xiaohui Xu2, Yufeng Zhou3, Ruiming Chang4

Central Odontogenic Fibroma with Unusual Presenting Symptoms

Aanchal Tandon, Bharadwaj Bordoloi, Safia Siddiqui, Rohit Jaiswal

The Prognostic Role of Lactate in Patients Who Achieved Return of Spontaneous Circulation after Cardiac Arrest: A Systematic Review and Meta‑analysis

Dongni Ren1, Xin Wang2, Yanyang Tu1,2

Inhibitory Effect of Hyaluronidase‑4 in a Rat Spinal Cord Hemisection Model

Xipeng Wang1,2, Mitsuteru Yokoyama2, Ping Liu3

Research and Development of Anticancer Agents under the Guidance of Biomarkers

Xiaohui Xu1, Guoyu Qiu1, Lupeng Ji2, Ruiping Ma3, Zilong Dang4, Ruling Jia1, Bo Zhao1

Idiopathic Hypereosinophilic Syndrome and Disseminated Intravascular Coagulation

Mansoor C. Abdulla

Phosphorylation of BRCA1‑Associated Protein 1 as an Important Mechanism in the Evasion of Tumorigenesis: A Perspective

Guru Prasad Sharma1, Anjali Geethadevi2, Jyotsna Mishra3, G. Anupa4, Kapilesh Jadhav5,
K. S. Vikramdeo6, Deepak Parashar2

Progress in Diagnosis and Treatment of Mixed Adenoneuroendocrine Carcinoma of Biliary‑Pancreatic System

Ge Zengzheng1, Huang-Sheng Ling2, Ming-Feng Li2, Xu Xiaoyan1, Yao Kai1, Xu Tongzhen3,
Ge Zengyu4, Li Zhou5

Surface-Enhanced Raman Spectroscopy to Study the Biological Activity of Anticancer Agent

Guoyu Qiu1, Xiaohui Xu1, Lupeng Ji2, Ruiping Ma3, Zilong Dang4, Huan Yang5

Alzheimer’s Disease Susceptibility Genes in Malignant Breast Tumors

Steven Lehrer1, Peter H. Rheinstein2

OSMCC: An Online Survival Analysis Tool for Merkel Cell Carcinoma

Umair Ali Khan Saddozai1, Qiang Wang1, Xiaoxiao Sun1, Yifang Dang1, JiaJia Lv1,2, Junfang Xin1, Wan Zhu3, Yongqiang Li1, Xinying Ji1, Xiangqian Guo1

Protective Activity of Selenium against 5‑Fluorouracil‑Induced Nephrotoxicity in Rats

Elias Adikwu, Nelson Clemente Ebinyo, Beauty Tokoni Amgbare

Advances on the Components of Fibrinolytic System in Malignant Tumors

Zengzheng Ge1, Xiaoyan Xu1, Zengyu Ge2, Shaopeng Zhou3, Xiulin Li1, Kai Yao1, Lan Deng4

A Patient with Persistent Foot Swelling after Ankle Sprain: B‑Cell Lymphoblastic Lymphoma Mimicking Soft‑tissue Sarcoma

Crystal R. Montgomery‑Goecker1, Andrew A. Martin2, Charles F. Timmons3, Dinesh Rakheja3, Veena Rajaram3, Hung S. Luu3

Coenzyme Q10 and Resveratrol Abrogate Paclitaxel‑Induced Hepatotoxicity in Rats

Elias Adikwu, Nelson Clemente Ebinyo, Loritta Wasini Harris

Progress in Clinical Follow‑up Study of Dendritic Cells Combined with Cytokine‑Induced Killer for Stomach Cancer

Ling Wang1,2, Run Wan1,2, Cong Chen1,2, Ruiliang Su1,2, Yumin Li1,2

Supraclavicular Lymphadenopathy as the Initial Manifestation in Carcinoma of Cervix

Priyanka Priyaarshini1, Tapan Kumar Sahoo2

ABO Typing Error Resolution and Transfusion Support in a Case of an Acute Leukemia Patient Showing Loss of Antigen Expression

Debasish Mishra1, Gopal Krushna Ray1, Smita Mahapatra2, Pankaj Parida2

Protein Disulfide Isomerase A3: A Potential Regulatory Factor of Colon Epithelial Cells

Yang Li1, Zhenfan Huang2, Haiping Jiang3

Clinicopathological Association of p16 and its Impact on Outcome of Chemoradiation in Head‑and‑Neck Squamous Cell Cancer Patients in North‑East India

Srigopal Mohanty1, Yumkhaibam Sobita Devi2, Nithin Raj Daniel3, Dulasi Raman Ponna4,
Ph. Madhubala Devi5, Laishram Jaichand Singh2

Potential Inhibitor for 2019‑Novel Coronaviruses in Drug Development

Xiaohui Xu1, Zilong Dang2, Lei Zhang3, Lingxue Zhuang4, Wutang Jing5, Lupeng Ji6, Guoyu Qiu1

Best‑Match Blood Transfusion in Pediatric Patients with Mixed Autoantibodies

Debasish Mishra1, Dibyajyoti Sahoo1, Smita Mahapatra2, Ashutosh Panigrahi3

Characteristics and Outcome of Patients with Pheochromocytoma

Nadeema Rafiq1, Tauseef Nabi2, Sajad Ahmad Dar3, Shahnawaz Rasool4

Comparison of Histopathological Grading and Staging of Breast Cancer with p53‑Positive and Transforming Growth Factor‑Beta Receptor 2‑Negative Immunohistochemical Marker Expression Cases

Palash Kumar Mandal1, Anindya Adhikari2, Subir Biswas3, Amita Giri4, Arnab Gupta5,
Arindam Bhattacharya6

Chemical Compositions and Antiproliferative Effect of Essential Oil of Asafoetida on MCF7 Human Breast Cancer Cell Line and Female Wistar Rats

Seyyed Majid Bagheri1,2, Davood Javidmehr3, Mohammad Ghaffari1, Ehsan Ghoderti‑Shatori4

Cyclooxygenase‑2 Contributes to Mutant Epidermal Growth Factor Receptor Lung Tumorigenesis by Promoting an Immunosuppressive Environment

Mun Kyoung Kim1, Aidin Iravani2, Matthew K. Topham2,3

Potential role of CircMET as A Novel Diagnostic Biomarker of Papillary Thyroid Cancer

Yan Liu1,2,3,4#, Chen Cui1,2,3,4#, Jidong Liu1,2,3,4, Peng Lin1,2,3,4,Kai Liang1,2,3,4, Peng Su5, Xinguo Hou1,2,3,4, Chuan Wang1,2,3,4, Jinbo Liu1,2,3,4, Bo Chen6, Hong Lai1,2,3,4, Yujing Sun1,2,3,4* and Li Chen 1,2,3,4*

Cuproptosis-related Genes in Glioblastoma as Potential Therapeutic Targets

Zhiyu Xia1,2, Haotian Tian1, Lei Shu1,2, Guozhang Tang3, Zhenyu Han4, Yangchun Hu1*, Xingliang Dai1*

Cancer Diagnosis and Treatments by Porous Inorganic Nanocarriers

Jianfeng Xu1,2, Hanwen Zhang1,2, Xiaohui Song1,2, Yangong Zheng3, Qingning Li1,2,4*

Delayed (20 Years) post-surgical Esophageal Metastasis of Breast Cancer - A Case Report

Bowen Hu1#, Lingyu Du2#, Hongya Xie1, Jun Ma1, Yong Yang1*, Jie Tan2*

Subtyping of Undifferentiated Pleomorphic Sarcoma and Its Clinical Meaning

Umair Ali Khan Saddozai, Zhendong Lu, Fengling Wang, Muhammad Usman Akbar, Saadullah Khattak, Muhammad Badar, Nazeer Hussain Khan, Longxiang Xie, Yongqiang Li, Xinying Ji, Xiangqian Guo

Construction of Glioma Prognosis Model and Exploration of Related Regulatory Mechanism of Model Gene

Suxia Hu, Abdusemer Reyimu, Wubi Zhou, Xiang Wang, Ying Zheng, Xia Chen, Weiqiang Li, Jingjing Dai

ESRP2 as a Non-independent Potential Biomarker-Current Progress in Tumors

Yuting Chen, Yuzhen Rao, Zhiyu Zeng, Jiajie Luo, Chengkuan Zhao, Shuyao Zhang

Resection of Bladder Tumors at the Ureteral Orifice Using a Hook Plasma Electrode: A Case Report

Jun Li, Ziyong Wang, Qilin Wang

Structural Characterization and Bioactivity for Lycium Barbarum Polysaccharides

Jinghua Qi1,2,  Hangping Chen3,Huaqing Lin2,4,Hongyuan Chen1,2,5* and Wen Rui2,3,5,6*

The Role of IL-22 in the Prevention of Inflammatory Bowel Disease and Liver Injury

Xingli Qi1,2, Huaqing Lin2,3, Wen Rui2,3,4,5 and Hongyuan Chen1,2,3

RBM15 and YTHDF3 as Positive Prognostic Predictors in ESCC: A Bioinformatic Analysis Based on The Cancer Genome Atlas (TCGA)

Yulou Luo1, Lan Chen2, Ximing Qu3, Na Yi3, Jihua Ran4, Yan Chen3,5*

Mining and Analysis of Adverse Drug Reaction Signals Induced by Anaplastic Lymphoma Kinase-Tyrosine Kinase Inhibitors Based on the FAERS Database

Xiumin Zhang1,2#, Xinyue Lin1,3#, Siman Su1,3#, Wei He3, Yuying Huang4, Chengkuan Zhao3, Xiaoshan Chen3, Jialin Zhong3, Chong Liu3, Wang Chen3, Chengcheng Xu3, Ping Yang5, Man Zhang5, Yanli Lei5*, Shuyao Zhang1,3*

Advancements in Immunotherapy for Advanced Gastric Cancer

Min Jiang1#, Rui Zheng1#, Ling Shao1, Ning Yao2, Zhengmao Lu1*

Tumor Regression after COVID-19 Infection in Metastatic Adrenocortical Carcinoma Treated with Immune Checkpoint Blockade: A Case Report

Qiaoxin Lin1, Bin Liang1, Yangyang Li2, Ling Tian3*, Dianna Gu1*

Mining and Analysis of Adverse Events of BRAF Inhibitors Based on FDA Reporting System

Silan Peng1,2#, Danling Zheng1,3#, Yanli Lei4#, Wang Chen3, Chengkuan Zhao3, Xinyue Lin1, Xiaoshan Chen3, Wei He3, Li Li3, Qiuzhen Zhang5*, Shuyao Zhang1,3*

Malignant Phyllodes Tumor with Fever, Anemia, Hypoproteinemia: A Rare and Strange Case Report and Literature Review

Zhenghang Li1, Yuxian Wei1*

Construction of Cuproptosis-Related LncRNA Signature as a Prognostic Model Associated with Immune Microenvironment for Clear-Cell Renal Cell Carcinoma

Jiyao Yu1#, Shukai Zhang2#, Qingwen Ran3, Xuemei Li4,5,6*

PlaSciPub - Platform for Scientific Publications

Copyrights © 2021 - 2022 | Plascipub | All Rights Reserved